Chatow Lior, Nudel Adi, Nesher Iris, Hayo Hemo David, Rozenberg Perri, Voropaev Hanna, Winkler Ilan, Levy Ronnie, Kerem Zohar, Yaniv Zohara, Eyal Nadav
Eybna Technologies Ltd., Givat Hen 43905, Israel.
Life (Basel). 2021 Mar 29;11(4):290. doi: 10.3390/life11040290.
The activity of a new, terpene-based formulation, code-named NT-VRL-1, against Human Coronavirus (HCoV) strain 229E was evaluated in human lung fibroblasts (MRC-5 cells), with and without the addition of cannabidiol (CBD). The main constituents in the terpene formulation used for the experiment were beta caryophyllene, eucalyptol, and citral. The tested formulation exhibited an antiviral effect when it was pre-incubated with the host cells prior to virus infection. The combination of NT-VRL-1 with CBD potentiated the antiviral effect better than the positive controls pyrazofurin and glycyrrhizin. There was a strong correlation between the quantitative results from a cell-viability assay and the cytopathic effect seen under the microscope after 72 h. To the best of our knowledge, this is the first report of activity of a combination of terpenes and CBD against a coronavirus.
在添加和不添加大麻二酚(CBD)的情况下,对一种代号为NT-VRL-1的新型萜烯类制剂针对人冠状病毒(HCoV)229E毒株的活性在人肺成纤维细胞(MRC-5细胞)中进行了评估。用于该实验的萜烯制剂中的主要成分是β-石竹烯、桉叶油素和柠檬醛。当在病毒感染前将测试制剂与宿主细胞预孵育时,其表现出抗病毒作用。NT-VRL-1与CBD的组合比阳性对照药吡唑呋林和甘草甜素更能增强抗病毒效果。细胞活力测定的定量结果与72小时后在显微镜下观察到的细胞病变效应之间存在很强的相关性。据我们所知,这是萜烯类与CBD组合对冠状病毒活性的首次报道。